Sat, Aug 30, 2014, 5:04 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Cadence Design Systems Inc. Message Board

viperciara 80 posts  |  Last Activity: Jul 22, 2014 3:39 PM Member since: Aug 1, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • viperciara@gmail.com viperciara Jun 12, 2014 10:13 AM Flag

    I hope this is true!! This would be a medical break through! If it happened I would put the price up higher than $10 considering the population that has to take insulin shots everyday!

  • viperciara@gmail.com viperciara Jun 12, 2014 3:37 PM Flag

    Presentation Abstract


    Session: Advances in the Diagnosis and Treatment of Type 1 Diabetes

    Abstract Number: 174-OR

    Title: Phase I Trial Using Ex Vivo Expanded Polyclonal Tregs for Recent-Onset Type 1 Diabetes

    Presentation Start: 6/15/2014 8:15:00 AM

    Presentation End: 6/15/2014 8:30:00 AM

    Authors: STEPHEN E. GILTELMAN, KEVAN HEROLD, SRINATH SANDA, CHRISTINE TOROK, LINDA RINK, AMY L. PUTNAM, ANGELA P. LARES, WEIHONG LIU, MICHAEL LEE, S ALICE. LONG, DEBORAH PHIPPARD, NOEL WARNER, LISA M. MASIELLO, PETER H. SAYRE, JEFFREY A. BLUESTONE, San Francisco, CA, New Haven, CT, Seattle, WA, Bethesda, MD, San Jose, CA

    Abstract: Background: Type 1 diabetes (T1D) results from activation of autoantigen reactive T cells and failure to control these cells by regulatory T cells (Tregs) to maintain peripheral tolerance. In NOD mice, the adoptive transfer of Tregs can prevent and reverse T1D, suggesting they play a vital role in maintaining tolerance. From this and other findings, we postulate that Tregs will be a safe and effective T1D therapy in humans. We have developed methods to purify Tregs using flow cytometry-based cell sorting and expand polyclonal Tregs ~500-fold. Using a cGMP-compliant manufacturing method, we initiated a phase I dosing study to test the feasibility, safety, and pharmacokinetics of administering these cells to patients with recent onset T1D.
    Methods: This open label phase 1 study was open to subjects ages 18-45 with T1D of 3-24 months duration, stimulated C-peptide on mixed meal tolerance test 0.1 pmol/ml, and no chronic active disease. 4 dosing cohorts of 3-4 subjects were enrolled, with the Treg dose increasing from 5x106 up to 2.6 x109. Autologous Tregs (CD4+CD25+CD127lo) were isolated and expanded as described by Putnam et al., Diabetes 2009. The DNA in expanded Tregs was labeled with deuterated glucose in 2 cohorts to track their time in circulation and stability. Safety experience was the primary outcome, with secondary eva

  • viperciara@gmail.com by viperciara Jun 13, 2014 6:53 AM Flag

    This is just great!

    Sentiment: Strong Buy

  • Reply to

    NO NEW SECURITIES BEING ISSUED!!!

    by viperciara Jun 13, 2014 6:53 AM
    viperciara@gmail.com viperciara Jun 13, 2014 7:43 AM Flag

    If you read the headlines it sounds like they are issuing securities, then when you read the article it says they are not! I hate when they put deceiving headlines out!!!

    Sentiment: Strong Buy

  • Reply to

    Why aren't we seeing insiders buying?

    by stockdog87 Jun 12, 2014 5:16 PM
    viperciara@gmail.com viperciara Jun 13, 2014 8:18 AM Flag

    I agree and the moving average I believe suggest that they might get a little cheaper!

    Sentiment: Strong Buy

  • Reply to

    NO NEW SECURITIES BEING ISSUED!!!

    by viperciara Jun 13, 2014 6:53 AM
    viperciara@gmail.com viperciara Jun 13, 2014 8:36 AM Flag

    Presentation Abstract

    Session: Advances in the Diagnosis and Treatment of Type 1 Diabetes

    Abstract Number: 174-OR

    Title: Phase I Trial Using Ex Vivo Expanded Polyclonal Tregs for Recent-Onset Type 1 Diabetes

    Presentation Start: 6/15/2014 8:15:00 AM

    Presentation End: 6/15/2014 8:30:00 AM

    Authors: STEPHEN E. GILTELMAN, KEVAN HEROLD, SRINATH SANDA, CHRISTINE TOROK, LINDA RINK, AMY L. PUTNAM, ANGELA P. LARES, WEIHONG LIU, MICHAEL LEE, S ALICE. LONG, DEBORAH PHIPPARD, NOEL WARNER, LISA M. MASIELLO, PETER H. SAYRE, JEFFREY A. BLUESTONE, San Francisco, CA, New Haven, CT, Seattle, WA, Bethesda, MD, San Jose, CA

    Abstract: Background: Type 1 diabetes (T1D) results from activation of autoantigen reactive T cells and failure to control these cells by regulatory T cells (Tregs) to maintain peripheral tolerance. In NOD mice, the adoptive transfer of Tregs can prevent and reverse T1D, suggesting they play a vital role in maintaining tolerance. From this and other findings, we postulate that Tregs will be a safe and effective T1D therapy in humans. We have developed methods to purify Tregs using flow cytometry-based cell sorting and expand polyclonal Tregs ~500-fold. Using a cGMP-compliant manufacturing method, we initiated a phase I dosing study to test the feasibility, safety, and pharmacokinetics of administering these cells to patients with recent onset T1D.
    Methods: This open label phase 1 study was open to subjects ages 18-45 with T1D of 3-24 months duration, stimulated C-peptide on mixed meal tolerance test 0.1 pmol/ml, and no chronic active disease. 4 dosing cohorts of 3-4 subjects were enrolled, with the Treg dose increasing from 5x106 up to 2.6 x109. Autologous Tregs (CD4+CD25+CD127lo) were isolated and expanded as described by Putnam et al., Diabetes 2009. The DNA in expanded Tregs was labeled with deuterated glucose in 2 cohorts to track their time in circulation and stability. Safety experience was the primary outcome, with secondary eva Less

  • Reply to

    data! type 1 !!!

    by pjmquixxx Jun 16, 2014 7:37 AM
    viperciara@gmail.com viperciara Jun 16, 2014 9:14 AM Flag

    Then why are you on this board?? To me you would have to be a complete IDIOT to be wasting your time on something you feel is 10 yrs away!! OR

    Sentiment: Strong Buy

  • Reply to

    Why buy Sovaldi?

    by winningstox Jun 17, 2014 12:47 AM
    viperciara@gmail.com viperciara Jun 18, 2014 8:55 AM Flag

    If it can do what you say it does, go find 10 people who have documented Hep then put them on your treatment, show there cured, market it under the name winningstoxBS miracle pill and make a billion!

  • Reply to

    Question on Brian Nichols

    by mikefgadams Jun 18, 2014 2:33 PM
    viperciara@gmail.com viperciara Jun 19, 2014 5:21 AM Flag

    I wish he would write a article for the Fool on NBS, that place needs a good article with facts and not just speculation!

    Sentiment: Strong Buy

  • Reply to

    Question on Brian Nichols

    by mikefgadams Jun 18, 2014 2:33 PM
    viperciara@gmail.com viperciara Jun 19, 2014 11:03 AM Flag

    Believe me he gets more than a penny a post like you do! Why don't you grow-up and get a real job LOL! You have been here for a while under different names and you know what NOBODY CARES!! You and all your stupid names could not influence this stock or the market you are jest a pest!!

    Sentiment: Strong Buy

  • viperciara@gmail.com by viperciara Jun 23, 2014 8:06 AM Flag

    Well this looks like good news! Hopefully will be exposed to new investors and will bring the PPS up! June 27th!

    Sentiment: Strong Buy

  • Reply to

    NBS to join Russel 3000

    by viperciara Jun 23, 2014 8:06 AM
    viperciara@gmail.com viperciara Jun 23, 2014 8:40 AM Flag

    I have been trying to learn how to read the charts, LOL If I am doing it right could we expect nbs to go down a little bit further before a upward trend??

    Sentiment: Strong Buy

  • Reply to

    3D Printing Fund

    by twojugglers Jun 20, 2014 8:41 AM
    viperciara@gmail.com viperciara Jun 23, 2014 9:21 AM Flag

    It is really nice to see ONVO listed 3rd! I think with some good news on some Big Pharm purchasing some of their liver assays we will see this stock shoot up, once one Big Pharm gets in their will be a waiting list!

    Sentiment: Strong Buy

  • Reply to

    What is so controversial about this?

    by bearofbleecker Jun 21, 2014 1:35 PM
    viperciara@gmail.com viperciara Jun 23, 2014 9:27 AM Flag

    It is not yahoo it is some of the people on the board that flag your post! Mine disappear a lot and on the NBS board we have a guy that flags any good news! Several times I have not been able to post for days because I have been flagged by dumpers so much! It is a shame they don't have the ability to monitor these boards better! I know a lot of time if you put a url up it disappears!

    Sentiment: Strong Buy

  • Reply to

    NBS to join Russel 3000

    by viperciara Jun 23, 2014 8:06 AM
    viperciara@gmail.com viperciara Jun 23, 2014 6:17 PM Flag

    OMG do I remember JAZZ LOL sold at $80 still kicking myself in the rear!!

    Sentiment: Strong Buy

  • viperciara@gmail.com viperciara Jun 25, 2014 11:02 AM Flag

    Are you serious??? It is up 35% since the split!!!

    Sentiment: Strong Buy

  • Reply to

    new 8-k out

    by treene Jun 26, 2014 8:17 AM
    viperciara@gmail.com viperciara Jun 26, 2014 8:32 AM Flag

    YES YES YES!!!!

    Sentiment: Strong Buy

  • Reply to

    PR way overdue

    by balsski Jun 22, 2014 8:07 PM
    viperciara@gmail.com viperciara Jun 26, 2014 8:34 AM Flag

    Well bases are loaded now!!!!

  • Reply to

    Hi

    by turkturkturkturk Jun 25, 2014 7:48 PM
    viperciara@gmail.com viperciara Jun 26, 2014 8:43 AM Flag

    It is coming really soon!! Like a good step on Monday then I believe a steady up turn to about November then it will blow out of the water!!!

    Sentiment: Strong Buy

  • viperciara@gmail.com by viperciara Jun 26, 2014 9:01 AM Flag

    I just cant stop!!

    Sentiment: Strong Buy

CDNS
17.63+0.16(+0.92%)Aug 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.